Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization - Implications in treatment outcomes.
Hepatocellular carcinoma
Lymphopenia
PD-1
Time to Progression
Yttrium-90
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
30
07
2023
revised:
03
11
2023
accepted:
09
11
2023
medline:
22
11
2023
pubmed:
22
11
2023
entrez:
21
11
2023
Statut:
aheadofprint
Résumé
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Liver-directed therapies, including Patients with HCC receiving first-cycle In 84/88 patients with available follow-up imaging, 83% had a localized ORR with 63% having localized CR. For overall response, 71% and 54% experienced ORR and CR, respectively. Post- Elevated PD-1 expression on peripheral T cells is associated with increased risk of HCC progression and shorter time to progression in bridging/downstaging to transplant HCC patients undergoing first-cycle
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Liver-directed therapies, including
METHODS
METHODS
Patients with HCC receiving first-cycle
RESULTS
RESULTS
In 84/88 patients with available follow-up imaging, 83% had a localized ORR with 63% having localized CR. For overall response, 71% and 54% experienced ORR and CR, respectively. Post-
CONCLUSIONS
CONCLUSIONS
Elevated PD-1 expression on peripheral T cells is associated with increased risk of HCC progression and shorter time to progression in bridging/downstaging to transplant HCC patients undergoing first-cycle
Identifiants
pubmed: 37988841
pii: S0959-8049(23)00744-X
doi: 10.1016/j.ejca.2023.113442
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113442Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AJC, TS, and JG are paid consultant by Boston Scientific. All other authors declare that they have no competing interests.